Prognostic factors and clinical staging systems in multiple myeloma in the group of 237 patients from the years 1991-2002 treated with conventional chemotherapy I. Prognostic significance of selected clinical and laboratory markers;Prognostické faktory a klinické stážuvací systémy u mnohočetněho myelomu v souboru 237 nemocných léčených v období 1991-2002 konvenční chemoterapií

Klinicka Onkologie

Volumn 15, Issue SUPPL., 2002, Pages 7-14

  Scudla V ^a   Bacovsky J ^a   Vytrasova M ^a   Ordeltova M ^a   Papajik T ^a   Opichalova D ^a   Farbiakova V ^a   Srovnalik K ^a   Sumna E ^a   Kuca B ^a   Slezar J ^a   Heincova V ^a   Zivna J ^a   Lautnerova E ^a   Krajsova I ^a   Kubeckova M ^a   Schlemmer, P ^a   Gumulec, J ^a   Vranova M ^a   Micanikova M ^a   Novosadova L ^a   Lasota, Z ^a   Cihal K ^a   Martinek A ^a   more..

^a III Interni Klinika   (Czech Republic)

Author keywords

Cytokines cytoadhesive molecules; Multiple myeloma; Prognostic factors; Propidium iodide proliferative index of plasmocytes; Thymidinkinase

Indexed keywords

ADHESIVE AGENT; ALBUMIN; BETA 2 MICROGLOBULIN; CARBOPLATIN; CARMUSTINE; CREATINE; CYCLOPHOSPHAMIDE; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LOMUSTINE; MELPHALAN; MONOCLONAL ANTIBODY; PREDNISONE; PROPIDIUM IODIDE; SYNDECAN 1; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL COUNT; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMA CELL; PROGNOSIS; PROTEIN BLOOD LEVEL;

EID: 1242325091     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Adam, Z.: Přehled léčebných postupů u pacientů s mnohočetným myelomem, s. 81-88. In: Adam, Z., Hájek, R., Mayer, J. et al.: Mnohočetný Myelom a Další Monoklonální Gamapatie. 1. Vyd., Masarykova univerzita, Brno 1999, s.370.
2. Bartl, R., Frisch, B.: Clinical significance of bone marrow biopsy and plasma cell morphology in MM and MGUS. Path Biol,47,1999,158-168.
3. Bataille, R., Durie, B.G.M., Grenier, J. et al.: Prognostic factors and staging in multiple myeloma: A Reappraisal. J Clin Oncol,4,1986,80-87.
4. 2 microglobulin produce a simple and powerful myeloma staging system. Blood,80,1992,733-737.
5. Blade, J., Kyle, R.A., Greipp, P.: Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Brit J Haematol,93,1996,345-351.
6. st Edit., Oxford University Press,Oxford 1995, s.581.
7. Boccadoro, M., Pileri, A.: Diagnosis, prognosis and standard treatment of multiple myeloma. Hematol Oncol North Amer,11,1997,111-131.
8. 2-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy. Haematologica,84,1999,905-910.
9. Cimino, G., Avvisati, G., Amadori, S. et al.: High serum IL-2 levels are predictive of prologed survival in multiple myeloma. Brit J Haematol, 75,1990,373-377.
10. Corrado, C., Santarelli, M.T., Pavlovsky, S. et al.: Prognostic factors in multiple myeloma. Definition of risk groups in 410 previously untreated patients: A Grupo Argentino de Tratamiento de la Leucemia Aguda Study. J Clin Oncol,12,1989,1839-1844.
11. Corso, A., Klersy, C., Lazzarino, M. et al.: Multiple myeloma in younger patients: The role of age as prognostic factor. Ann Hematol,76,1998,67-72.
12. Drach, J., Ackermann, J., Fritz, E. et al.: Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood,92,1998,802-809.
13. Durie, B.G.M., Salmon, S.E., Moon, T.E.: Pretreatment tumour mass, cell kinetics and prognosis in multiple myeloma. Blood,55,1980,364-372.
14. 2 microglobulin in myeloma: A Southwest Oncology Group Study. Blood,75,1990,823-830.
15. Fonseca, R.: Prognostic Implications of Chromosomal Abnormalities as Detected by FISH. Abstr. VIII International Myeloma Workshop, Banff 2001,17-18.
16. Greipp, P.R.: Advances in the diagnosis and management of myeloma. Sem Hematol,29,1992,Suppl.2,24-45.
17. 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood,81,1993,3382-3387.
18. Greipp, P.R.: Prognosis in myeloma (review). Mayo Clin Proc, 69, 1994, 895-902.
19. rd Edit., Churchille-Livingstone, New York 1996.
20. Greipp, P.R., Leong, T., Bennett, J.M. et al.: Plasmablastic morphology - An independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG). Blood,91,1998,2501-2507.
21. Greipp, P. R., Trendle, M. C., Leong, T. et al.: Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leukemia/Lymphoma, 35,1999,83-89.
22. Greipp, P.R., San Miguel, J. and Myeloma prognostic index working group: Progres Towards an International Prognostic Index for Multiple Myeloma. Abstr. VIII International Myeloma Workshop, Banff 2001,58.
23. Grignani, G., Gobbi, P.G., Formisano, R. et al.: A prognostic index for multiple myeloma. Brit J Cancer,73,1996,1101-1107.
24. Haferlach, T., Löffler, H.: Prognostic factors in multiple myeloma: Practicability for clinical practice and future perspectives. Leukemia,11,1997,5-9.
25. Knudsen, L.M., Hjorth, M., Hippe, E.: Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Eur J Haematol, 65, 2000, 175-181.
26. Kyle, R.A.: Prognostic factors in multiple myeloma. Hematol Oncol, 6, 1988, 125-130.
27. Kyle, R.A.: Why better prognostic factors for multiple myeloma are needed. Blood,83,1994,1713-1716.
28. Kyrtsonis, M.C., Dedoussis, G., Zervas, C. et al.: Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Brit J Haematol,93,1996,398-400.
29. Mariette, X., Zagdanski, A.M., Guermazi, A. et al.: Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Brit J Haematol,104,1999,723-729.
30. Merlini, G., Perfetti, V., Gobbi, P. et al.: Acute phase protein and prognosis in multiple myeloma. Brit J Haematol,83,1993,595-601.
31. Michiels, J.J.: Multiple myeloma: Prognostic factors and treatment modalities. Nether J Med,40,1992,254-270.
32. Murakami, H., Kawada, T., Saitoh, T. et al.: A staging system for multiple myeloma based on the morphology of myeloma cells. Eur J Haematol,62, 1999,63-67.
33. Nehemiah, C., Cherng, P., Nabih, R. et al.: Prognostic factors in multiple myeloma. Cancer,67,1991,3150-3156.
34. Ohtani, K., Ninomiya, H., Hasegawa, Y. et al.: Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias. Brit J Haematol,91,1995,116-120.
35. Oivanen, T.M.: Prognostic value of serum M-protein doubling time at escape from plateau of multiple myeloma. The Finnish Leukaemia Group. Eur J Haematol,57,1996,247-253.
36. 138/propidium iodide double staining technique. Cytometry,17, 1994,332-339.
37. Österborg, A., Mellstedt, H.: Clinical features and staging multiple myeloma, s.98-107. In.: Gahrton, G., Durie, B.G.M.: Multiple Myeloma. Arnold,London 1996,s.219.
38. Peest, D., Coldewey, R., Deicker, H. et al.: Prognostic values clinical, laboratory, and histological characteristics in multiple myeloma: Improved definition of risk groups. Eur J Cancer,29,1993,978-985.
39. Pulkki, K., Peleiniemi, T.T., Rajamaki, A. et al.: Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Brit J Haematol,92,1996,370-374.
40. Raaijmakers, H.G.P., Izaquierdo, M.A.I., Lokhorst, H.M. et al.: Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood,91,1998,1029-1036.
41. Rajkumar, S.V., Greipp, P.R.: Prognostic factors in multiple myeloma. Hematol Oncol Clin North Amer,13,1999,1295-1314.
42. Rajkumar, S.V., Fonseca, R., Lacy, M.Q. et al.: Plasmablastic morphology is on independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J Clin Oncol,17,1999,1551-1557.
43. Rajkumar, S.V., Leong, T., Roche, P.C. et al.: Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res,6,2000,3111-3116.
44. Rodon, P., Linassier, C., Gauvain, J.B. et al.: Multiple myeloma in elderly patients: Presenting features and outcome. Eur J Haematol,66,2001,11-17.
45. Sakalová, A. et al.: Generalizovaný Plazmocytóm. 1. Vyd., Veda, Bratislava 1983,s.231.
46. San Miguel, J.F., García-Sanz, R., Gonzáles, M. et al.: A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood,85,1995,448-455.
47. San Miguel, J.F.: Overview of Prognostic Factors in Multiple Myeloma. Abstr. VI. International Workshop on Multiple Myeloma. Boston 1997.
48. Seidel, C., Borset, M., Turesson, I. et al.: Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood,91,1998,806-812.
49. Seidel, C., Sundan, A., Hjorth, M. et al.: Serum syndecan-1: A new independent prognostic marker in multiple myeloma. Blood,95,2000,388-392.
50. Sezer, O., Niemoller, K., Eucker, J. et al.: Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol,79,2000,574-577.
51. 2-microglobulin. Am J Clin Pathol,106,1996,64-68.
52. Simonsson, B., Källander, C.F.R., Brenning, G. et al.: Biochemical markers in multiple myeloma: A multivariate analysis. Brit J Haematol, 69,1988,47-53.
53. Sonoki, T., Hata, H., Kuribayashi, N. et al.: Expression of PRAD1/cyclin D1 in plasma cell malignancy: Incidence and prognostic aspects. Brit J Haematol,104,1999,614-617.
54. Stasi, R., Brunetti, M., Parma, A. et al.: The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer,82, 1998,1860-1866.
55. Ščudla, V., Wiedermann, B., Wiedermann, D. et al.: Význam prognostických ukazatelů u mnohočetného myelomu I. Klinické, biochemické a radiografické ukazatele. Vnitř Leók, 30,1984,1145-1155; II. Vybrané hematologické ukazatele. Vnitř Lék,30,1984,1156-1165.
56. Ščudla, V., Indrák, K.: Prognostic significance of stratification systems in multiple myeloma. I. Risk categories (good and poor risk). Neoplasma,32,1985,469-478. II. Clinical staging sytems. Neoplasma, 32,1985,481-493.
57. Ščudla, V., Wiedermann, B., Kodousek, R. et al.: Significance of nucleocytoplasmic maturation asynchrony in multiple myeloma. Neoplasma, 33,1986,483-492.
58. Ščudla, V., Budíková, M., Fischerová, E. et al.: Stratification of multiple myeloma according to serum beta2-microglobulin and serum albumin levels. Acta Univ Palacki Olomuc,130,1991,201-212.
59. Ščudla, V., Bačovský, J., Papajík, T. et al.: Tymidinkináza séra u mnohotného myelomu. I. Vztah k vybraným laboratorním ukazatelům nemoci. Vnitř Lék,40,1994,151-156. II. Vztah k aktivité a rozsahu nemoci. Vnitř. Lék,40,1994,157-162.
60. Ščudla, V., Bačovský, J., Budíková, M. et al.: Interleukin-6 v séru u mnohočetného myelomu: I. Vztah k vybraným laboratornim ukazatelům nemoci. Vnitř Lék,41,1995,593-598. II. Vztah k aktivité a k pokročlosti nemoci. Vnitř Lék,41,1995,599-604.
61. Ščudla, V., Kubalová, D., Bačovský, J. et al.: Příspévek k vyšetření solubilního receptoru interleukinu-6 v séru u mnohočetného myelomu. Čas Lék čes,135,1996,719-722.
62. Ščudla, V.: Pokroky v léčbě mnohočetného myelomu. Vnitř. Lék., 43, 1997,529-536.
63. Ščudla, V., Budíková, M., Bačovský, J. et al.: Vztah hladin solubilních cytoadhezivních molekul VCAM-1 a ICAM-1 k vybraným klinickým a laboratorním ukazatelům mnohočetného myelomu. Vnitř Lék,45,1999,583-590.
64. Ščudla, V., Ordeltová, M., Špidlová, A. et al.: Význam vyšetření propidium-jodidového indexu plazmocytů u mnohočetného myelomu. I. Vztah k vybraným laboratorním ukazatelům nemoci. Vnitř Lék, 45,1999,331-335. II. Vztah k rozsahu a k aktivité nemoci. Vnitř Lék,45, 1999,336-341.
65. Ščudla, V., Bačovský, J.: Prognostické faktory u mnohočetného myelomu. s. 157-173. In: Adam, Z., Hájek, R., Mayer, J. et al.: Mnohočetný Myelom a Další Monoklonální Gamapatie. 1.Vyd. Masarykova univerzita, Brno 1999, s. 370.
66. Ščudla, V., Ordeltová, M.: Klinický a biologický význam vyšetřování proliferačních charakteristik plazmocytů u mnohočetného myelomu, s.175-184. In: Adam, Z., Hájek, R., Mayer, J. et al.: Mnohočetný Myelom a Další Monoklonální Gamapatie. 1.Vyd. Masarykova univerzita, Brno 1999,s.370.
67. Špička, I., Merta, M., Cieslar, P. et al.: Postižení ledvin u monoklonálních gamapatií. Čas Lék čes,134,1995,478-481.
68. Špička, I., Cieslar, P., Procházka, B. et al.: Prognostické faktory a markery aktivity u mnohočetného myelomu. Čas Lék čes,139,2001,208-212.
69. Tienhaara, A., Pulkki, K., Mattila, K. et al.: Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis. Brit J Haematol, 86,1994,391-393.
70. Trendle, M.C., Leong, T., Kyle, R.A. et al.: Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cig) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E 9486. Amer J Hematol,61,1999,232-237.
71. Turesson, I, Abildgaard, N., Ahlgren, T. et al.: Prognostic evaluation in multiple myeloma: An analysis of the impact of new prognostic factors. Brit J Haematol,106,1999, 1005-1012.
72. Weber, D.M., Dimopoulos, M.A., Moulopoulos, L.A. et al.: Prognostic features of asymptomatic multiple myeloma. Brit J Haematol, 97, 1997, 810-814.
73. Wijdenes, J., Vooijs, W.C., Clément, C. et al.: A plasmocyte selective monoclonal antibody (B-B4) recognize syndecan-1. Brit J Haematol, 94,1996,318-323.
74. Witzig, T., Gertz, M.A., Lust, J.A. et al.: Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood,88,1996,1780-1787.
75. Witzig, T.E., Timm, M., Larson, D. et al.: Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Brit J Haematol,104,1999,131-137.